- Home
- CGNT vs PHAT Comparison
CGNT vs PHAT Comparison
Compare CGNT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | PHAT |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Israel | United States |
| Employees | N/A | 371 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.2M | 590.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CGNT | PHAT |
|---|---|---|
| Price | $8.66 | $7.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $12.33 | ★ $20.45 |
| AVG Volume (30 Days) | 584.5K | ★ 1.1M |
| Earning Date | 09-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $11.71 | $80.50 |
| Revenue Next Year | $10.33 | $56.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $6.29 | $6.91 |
| 52 Week High | $12.31 | $18.31 |
Technical Indicators
Market Signals| Indicator | CGNT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 37.55 |
| Support Level | $7.88 | $6.91 |
| Resistance Level | $8.98 | $9.74 |
| Average True Range (ATR) | 0.26 | 0.39 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 81.17 | 23.18 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.